Mp66-02 survival analysis of patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy with or without a neoadjuvant tyrosine kinase inhibitor
Metastatic renal cell carcinoma portends a poor prognosis with a 5-year overall survival (OS) of only 8%. We evaluated whether neoadjuvant tyrosine kinase inhibitors (TKI) prolongs OS in patients undergoing cytoreductive nephrectomy (CN) using the National Cancer Database (NCDB).
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Jing Zhi Lo, Peter Sunaryo, David Paulucci, Ketan Badani Tags: Kidney Cancer: Advanced (including Drug Therapy) II Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Databases & Libraries | Kidney Cancer | Neoadjuvant Therapy | Nephrectomy | Renal Cell Carcinoma | Urology & Nephrology